In April, Oklahoma Governor Kevin Stitt ordered the purchase of $2 million worth of the drug, and now the Attorney Generals' office is being asked to return it.
Hydroxychloroquine does not improve clinical outcomes in hospitalized COVID-19 patients.
James P. Kiley, Ph.D., director, Division of Lung Diseases at NHLBI.
Once the drug became continuously mention by Donald Trump, health officials began attempting to sway citizens away from it, as it can have serious side effects such as irregular heart rhythms and even death.
While many states also made purchases of hydroxychloroquine, Oklahoma was one of just two to buy the drug from a private pharmaceutical wholesaler.
It is not yet know how much of the $2 million purchase the state will be able to get back from the supplier, California-based FFF Enterprises, Inc.